Illumina, Inc.
As of Oct 22, 2026, Illumina is in Stage 2, the uptrend phase, now in week 24 (since May 6, 2026). It closed at $269.40, 8.3% below its 52-week high and above its 200-day average, which is rising.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is ILMN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ILMN among Diagnostics & Research3rd of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
Illumina: quick answers
What stage is Illumina in?
As of Oct 22, 2026, Illumina (ILMN) is in Stage 2, the uptrend phase. It entered Stage 2 on May 6, 2026 and is in week 24. What the four stages mean
Is Illumina in an uptrend?
Yes. Illumina is in a Stage 2 uptrend. It trades 56.4% above its 200-day average, which is rising.
How far is Illumina from its 52-week high?
Illumina closed at $269.40 on Oct 22, 2026, 8.3% below its 52-week high of $293.69. Its 52-week low is $95.03.
How has Illumina performed over the past year?
As of Oct 22, 2026, Illumina is up 172.2% over the past year and up 100.5% so far in 2026.
Which sector and industry is Illumina in?
Illumina is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.